Logo image
Se connecter
Retour
Combination of rapamycin and adipose-derived mesenchymal stromal cells enhances therapeutic potential for osteoarthritis
Article de revue   Open Access   Avec comité de lecture

Combination of rapamycin and adipose-derived mesenchymal stromal cells enhances therapeutic potential for osteoarthritis

Damien Veret, Gautier Tejedor, Esther Perez, Alison Chomette, Maylis Farno, Rosanna Ferreira-Lopez, Louis Dagneaux, Yves-Marie Pers, Christian Jorgsensen, Claire Gondeau, …
Stem Cell Research and Therapy, Vol.16(1)
15/01/2025
DOI: https://doi.org/10.1186/s13287-024-04090-8
PMCID: PMC11737215
PMID: 39815291

Résumé

Osteoarthritis Mesenchymal stromal/stem cells Regenerative medicine Rapamycin Mesenchymal Stem Cells Middle Aged Collagen Type II Humans Indoleamine-Pyrrole 2,3,-Dioxygenase Sirolimus Chondrocytes Cell Differentiation Adipose Tissue SOX9 Transcription Factor Mesenchymal Stem Cell Transplantation Collagen Type I, alpha 1 Chain Cyclooxygenase 2 Cellular Senescence Chondrogenesis Collagen Type I Male Female Aged Cells, Cultured
The regenerative potential of mesenchymal stromal/stem cells (MSCs) has been extensively studied in clinical trials in the past decade. However, despite the promising regenerative properties documented in preclinical studies, for instance in osteoarthritis (OA), the therapeutic translation of these results in patients has not been fully conclusive. One factor contributing to this therapeutic barrier could be the presence of senescent cells in OA joints.

Fichiers et liens (2)

url
Find in HALAfficher
url
https://doi.org/10.1186/s13287-024-04090-8Afficher
Published (Version of record) Ouvrir

Indicateurs

1 Consultations de la notice

Détails

Logo image